youtube_live
Q3 2026 earnings • released • EPS beat +27.23% • Revenue beat +128.58%
See resultschevron_right
EDIT:NASDAQ
Editas Medicine Inc
$2.40
arrow_downward
-4.03%(-0.10) 1D
Nov 11, 9:42:45 AM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
$2.51
High
$2.52
Low
$2.40
Mkt. cap
369.21M
Avg. vol.
2.33M
Volume
106.25K
52-wk high
$3.94
52-wk low
$1.66
EPS
-$0.62
Beta
2.09
Shares outstanding
154.34M
No. of employees
87
Open
$2.51
High
$2.52
Low
$2.40
Mkt. cap
369.21M
Avg. vol.
2.33M
Volume
106.25K
52-wk high
$3.94
52-wk low
$1.66
EPS
-$0.62
Beta
2.09
Shares outstanding
154.34M
No. of employees
87
News stories
From web sources and news partners
TradingView
·
2 days ago
Editas Medicine, Inc. reports results for the quarter ended September 30 - Earnings Summary
Zacks
·
2 days ago
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
Investing.com
·
2 days ago
Editas Medicine earnings beat by $0.04, revenue topped estimates
kare11.com
·
2 days ago
Editas: Q3 Earnings Snapshot
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc
CEO-
Employees87
FoundedNov 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteeditasmedicine.com